title: Telavancin (Theravance).
abstract: Theravance is developing telavancin, an injectable peptidoglycan inhibitor antibiotic for potential use in the treatment of Gram-positive bacterial infection. Phase III trials in complicated skin and skin structure infections commenced in September 2004.
authors.affiliation: LifeNet Inc, R&D Department, Virginia Beach, VA 23455, USA. jlpymp@yahoo.com
authors.forename: John L
authors.initials: JL
authors.lastname: Pace
authors.forename: J Kevin
authors.initials: JK
authors.lastname: Judice
mesh_terms: D000617:Aminoglycosides / Q000009:adverse effects / Q000138:chemical synthesis / Q000378:metabolism / Q000493:pharmacokinetics / Q000494:pharmacology* / Q000627:therapeutic use; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D017326:Clinical Trials, Phase III as Topic; D000075202:Contraindications; D004353:Drug Evaluation, Preclinical; D016908:Gram-Positive Bacterial Infections / Q000188:drug therapy* / Q000382:microbiology; D000077427:Lipoglycopeptides; D013329:Structure-Activity Relationship
chemical_list: D000617:Aminoglycosides; D000077427:Lipoglycopeptides; C487637:telavancin